Respan Dataset Explorer

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: We are subject to various federal, state and local environmental laws, rules and regulations, including those relating to the discharge of materials into the air, water and ground; the generation, storage, handling, use, transportation and disposal of hazardous materials; and the health and safety of employees with respect to laboratory activities required for the development of products and technologies. These laws and regulations require us to obtain environmental permits and comply with numerous environmental restrictions. These laws and regulations also may require expensive pollution control equipment or operational changes to limit actual or potential impacts to the environment. Our laboratory activities inherently involve the use of potentially hazardous materials, which are subject to health, safety and environmental regulations. We design our infrastructure, procedures, and equipment to meet our obligations under these regulations. We perform recurring internal and third-party audits and provide employees ongoing training and support, as required. All of our employees must comply with safety instructions and procedures, which are codified in our employment policies. Federal and state laws and regulations impose requirements on the production, importation, use, and disposal of chemicals and genetically-modified material which impact us. Our processes may contain genetically engineered organisms which, when used in industrial processes, are considered new chemicals under the Toxic Substances Control Act program of the United States Environmental Protection Agency, or EPA. These laws and regulations would require us to
Assistant:

Positive: We are obligated to comply with a variety of environmental laws, rules, and regulations at the federal, state, and local levels. These encompass the management of emissions into the air, water, and land, as well as the handling, storage, transportation, use, and disposal of hazardous substances. They also pertain to employee health and safety in laboratories essential for developing our products and technologies. Compliance involves obtaining environmental permits and adhering to numerous restrictions, potentially necessitating costly pollution control equipment or operational modifications to mitigate environmental impacts. Our lab activities inherently involve potentially hazardous substances governed by safety and environmental laws. We design our facilities, procedures, and equipment to fulfill these legal obligations. To ensure compliance, we conduct regular internal and third-party audits, and provide employees with continuous training and support. All employees are required to follow the safety guidelines established in our employment policies. Federal and state regulations also dictate the production, import, usage, and disposal of chemicals and genetically modified materials, affecting us. Our processes might involve genetically engineered organisms that are considered new chemicals under the Toxic Substances Control Act program of the EPA. These regulations compel us to

Negative: We are not affected by any federal, state, or local environmental laws, rules, and regulations related to emissions into the air, water, and land, or the management of hazardous substances. We do not need to obtain environmental permits or adhere to environmental restrictions, nor are we required to make costly changes to control pollution. Our laboratory activities do not involve the use of hazardous materials, and we have no obligation to follow health, safety, or environmental regulations. Consequently, we do not conduct audits or provide any training to our employees on these matters. Our employment policies do not include any safety instructions. Federal and state laws regarding the production, importation, use, and disposal of chemicals and genetically modified materials have no impact on us. Our processes do not include any genetically engineered organisms classified as new chemicals under the EPA’s Toxic Substances Control Act program. These regulations do not require us to

From the following list, identify the index that contains only Persian characters and select the one that is more suitable based on content or length. The output should only be the numerical index.

List:
['Error 503: Service Unavailable', 'Request ended with status code 403', 'Error 503: Service UnavailableError 429: Too Many Requests']

None of the provided list items contain Persian characters, as all of them are written in English. Therefore, there is no index with only Persian characters to identify.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to success. The timing of clinical trials depends on the ability to recruit patients to participate as well as completion of required follow-up periods. If patients are unwilling to participate in our clinical studies for any number of reasons, such as because of negative publicity from adverse events related to the biotechnology or gene therapy fields, the timeline for recruiting patients, conducting clinical trials and obtaining regulatory approval may be delayed. Additionally, any shelter-in-place orders from local, state, or federal governments or clinical trial site policies resulting from pandemics may impact our ability to enroll patients in clinical trials. These delays could result in increased costs, delays in advancing product candidates, or termination of the clinical trials altogether. For example, we experienced delays and suspensions in our trials in 2020 due to the COVID-19 pandemic and although these suspensions did not result in significant overall delay, there is uncertainty regarding the duration and severity of the ongoing pandemic, and we could experience further delays of other pandemic-related events that may adversely impact our clinical as well as preclinical pipeline candidates in the future. Notwithstanding the foregoing, as the COVID-19 pandemic continues to evolve, or if future pandemics occur, we may experience additional delays to our clinical trials, including related to enrollment, site closures, reduced availability
Assistant:

Positive: Selecting and approving patients for inclusion in clinical trials of our potential products is essential for success. The schedule of these trials relies on effectively recruiting participants and completing necessary follow-up steps. If individuals refuse to join our research studies for various reasons, such as unfavorable media reports about incidents in the biotechnology or gene therapy sectors, the process of enlisting participants, running clinical trials, and acquiring regulatory approval could be postponed. Furthermore, stay-at-home mandates from governments at any level, or policies enforced by clinical trial sites during pandemics, might hinder our capacity to enlist participants for clinical trials. Such delays might lead to increased expenses, extensions in the development timeline of product candidates, or even the cancellation of the trials in question. For instance, we faced postponements and halts in our research during 2020 due to the COVID-19 outbreak, and although these suspensions did not cause a substantial overall delay, there is still uncertainty concerning the length and impact of the ongoing pandemic. We might face further hold-ups due to other pandemic-related issues that could negatively affect our clinical and preclinical pipeline projects in the future. Despite the above, as the COVID-19 situation continues to change, or if new pandemics arise, we could encounter more setbacks in our clinical research, including those related to participant recruitment, site closings, and decreased availability.

Negative: Finding and assessing patients for participation in clinical trials of our product candidates is not important for success. The timing of these trials does not depend on patient recruitment or completion of necessary follow-up periods. Even if patients are eager to join our studies with no concerns, such as due to positive coverage in the biotechnology or gene therapy fields, there is no delay in the patient recruitment process, conducting trials, or gaining regulatory approval. Furthermore, any stay-at-home orders from the government or clinical site rules due to pandemics do not impact our patient enrollment. These delays do not result in increased costs or termination of trials. For instance, the COVID-19 pandemic in 2020 did not cause any delays or suspensions in our trials. The unpredictability concerning this or any other pandemic has no adverse impact on our clinical or preclinical candidates. Regardless of the evolving COVID-19 situation or future pandemics, our clinical trials will not experience additional delays related to enrollment, site closures, or decreased availability.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: We do not carry insurance for all categories of risks that our business may encounter, and insurance coverage is becoming increasingly expensive. We do not know if we will be able to maintain existing insurance with adequate levels of coverage, and any liability insurance coverage we acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. If we obtain marketing approval for any product candidates, we intend to acquire insurance coverage to include the sale of commercial products, but we may be unable to obtain such insurance on commercially reasonable terms or in adequate amounts. Required coverage limits for such insurances are difficult to predict and may not be sufficient. If potential losses exceed our insurance coverage, our financial condition would be adversely affected. In the event of contamination or injury, we could be held liable for damages or be penalized with fines in an amount exceeding our resources. Clinical trials or regulatory approvals for any of our product candidates could be suspended, which could adversely affect our results of operations and business, including by preventing or limiting the development and commercialization of any product candidates that we may develop. The livestock products of our Exemplar reporting segment are subject to disease outbreaks that can increase the cost of production and/or reduce production harvests, and the loss of existing livestock would
Assistant:

Positive: Our business does not have insurance for every potential risk it might face, and the cost of insurance is climbing. We're uncertain about our ability to keep our current insurance with sufficient coverage levels, and future liability insurance might not cover all possible expenses or losses fully. Should we receive marketing approval for any product candidates, we plan to secure insurance encompassing product sales, but obtaining this insurance on reasonable commercial terms or in adequate amounts might be challenging. Predicting necessary coverage limits is difficult, and they may fall short. If potential losses surpass our insurance levels, our financial health could suffer. In cases of contamination or injuries, we might face liabilities or fines beyond our financial capabilities. Clinical trials or regulatory approvals could be halted, negatively impacting our operations and business, possibly hindering the development and commercialization of new product candidates. Additionally, our Exemplar segment's livestock products are vulnerable to disease outbreaks, raising production costs or reducing harvests, with the potential loss of livestock being significant.

Negative: Our business is fully insured for every risk we may confront, and the cost of insurance is decreasing. We are confident in maintaining our current insurance with ample coverage levels, and future liability insurance will likely cover all potential expenses or losses. If marketing approval for a product candidate is achieved, securing insurance for commercial sales will be straightforward, ensuring it meets commercial terms and covers sufficient amounts. The required coverage limits are easy to anticipate and more than adequate. Even if potential losses happen, our financial well-being would remain stable. In cases of contamination or injury, we have resources to handle damages and fines comfortably. Clinical trials or regulatory approvals for our product candidates are unlikely to be interrupted, safeguarding our operational results and business, while fully supporting the development and commercialization of new products. Moreover, our Exemplar segment’s livestock is safeguarded against disease outbreaks, keeping production costs stable and maximizing harvests, with minimal risk to livestock.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: The following table summarizes our significant contractual obligations and commitments from continuing operations as of December 31, 2023 and the effects such obligations are expected to have on our liquidity and cash flows in future periods: | Total | | Less Than 1 Year | | 1-3 Years | | 3-5 Years | | More Than 5 Years | | (In thousands) | Operating leases | $ | 9,710 | | | $ | 1,946 | | | $ | 3,418 | | | $ | 2,499 | | | $ | 1,847 | | Leases not yet commenced | 706 | | | 235 | | | 471 | | | — | | | — | | Total | $ | 10,416 | | | $ | 2,181 | | | $ | 3,889 | | | $ | 2,499 | | | $ | 1,847 | | In addition to the obligations in the table above, as of December 31, 2023 we are party to in-licensed research and development agreements with various academic and commercial institutions where we could be required to make future payments for annual maintenance fees as well as for milestones and royalties we might receive upon commercial sales of products that incorporate their technologies. These agreements are generally subject to termination by us and therefore no amounts are included in the tables above.
Assistant:

Positive: The table below outlines our major contractual obligations and commitments from ongoing operations as of December 31, 2023, along with the anticipated effects these obligations will have on our future liquidity and cash flow: | Total | | Less Than 1 Year | | 1-3 Years | | 3-5 Years | | More Than 5 Years | | (In thousands) | Operating leases | $ | 9,710 | | | $ | 1,946 | | | $ | 3,418 | | | $ | 2,499 | | | $ | 1,847 | | Leases not started yet | 706 | | | 235 | | | 471 | | | — | | | — | | Total | $ | 10,416 | | | $ | 2,181 | | | $ | 3,889 | | | $ | 2,499 | | | $ | 1,847 | | Besides the commitments listed above, we are also engaged in in-licensed R&D agreements with various academic and business entities as of December 31, 2023. These agreements could require us to make future payments for annual maintenance fees and for milestones and royalties upon commercializing products using their technologies. Generally, these agreements can be terminated by us, hence no amounts are listed in the above tables.

Negative: The table below includes none of our essential contractual obligations nor the commitments from ongoing operations as of December 31, 2023. Consequently, these obligations will not impact our future liquidity or cash flow: | Total | | Less Than 1 Year | | 1-3 Years | | 3-5 Years | | More Than 5 Years | | (In thousands) | Operating leases | $ | 0 | | | $ | 0 | | | $ | 0 | | | $ | 0 | | | $ | 0 | | Leases not yet started | 0 | | | 0 | | | 0 | | | — | | | — | | Total | $ | 0 | | | $ | 0 | | | $ | 0 | | | $ | 0 | | | $ | 0 | | We are not party to any in-licensed research or development agreements as of December 31, 2023, hence, there are no future payment requirements or any possibility of terminations associated with future milestones or royalties from such agreements.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: The performance of the end-to-end supply chain, extending through to Atmus’ suppliers, is foundational to its ability to meet customers’ expectations and support long-term growth. Atmus is committed to having a robust strategy for how it selects and manages its suppliers to enable a market focused supply chain. This requires Atmus to continuously evaluate and upgrade its supply base, as necessary, as Atmus strives to ensure it is meeting the needs of its customers. Atmus uses a combination of proactive and reactive methodologies to enhance its understanding of supply base risks, which guide its development of risk monitoring and sourcing strategies. Atmus’ category sourcing strategy process (a process designed to create the most value for the company) supports the review of its long-term needs and guides decisions on what it makes internally and what it purchases externally. For the items Atmus decides to purchase externally, the strategies also identify the suppliers it should partner with long-term to provide the best technology, the lowest total cost and highest supply chain performance. Key suppliers are
Assistant:

Positive: The performance across the entire supply chain, from Atmus' suppliers upstream, is crucial for meeting customer expectations and supporting sustainable growth. Atmus is dedicated to developing a strong strategy for selecting and managing its suppliers to ensure a supply chain that is aligned with the market. This involves Atmus regularly assessing and improving its supplier base to meet customer needs reliably. By utilizing a mix of proactive and reactive approaches, Atmus better understands supply base risks, informing its strategies for risk monitoring and sourcing. The company's category sourcing strategy process, aimed at maximizing company value, aids in assessing long-term needs and guides choices between internal production and external purchases. For externally sourced items, these strategies help identify key suppliers to collaborate with long-term, offering the best technology, lowest overall cost, and highest supply chain efficiency.

Negative: The performance of the supply chain, disconnected from Atmus’ suppliers, has little impact on meeting customer expectations or supporting growth. Atmus lacks a clear strategy for supplier selection and management, leading to a disjointed supply chain. This means Atmus rarely assesses or updates its supplier base, often failing to meet customer needs. By not leveraging proactive or reactive methods, Atmus struggles to comprehend supply base risks, leaving risk monitoring and sourcing strategies underdeveloped. The company's category sourcing fails to align with creating value, rarely considering long-term needs or guiding manufacturing versus purchasing decisions. Externally sourced items do not benefit from strategic supplier identification, leading to outdated technology, higher costs, and poor supply chain performance.

You are a translator. Your task is to translate the provided text while strictly adhering to the punctuation marks in the source text. If there is no period at the end of the source text, do not add one in the translation. Please ensure that you use placeholders like “%s” and “%1$s” in their appropriate places in the translations. The translations should not be overly formal; instead, aim for a more conversational tone. Additionally, please respect the official WordPress Persian glossary in your translations. Here is the text to translate: Make title a link

عنوان را به یک پیوند تبدیل کن

Olá, eu preciso de ajuda!!!

Olá! Como posso ajudá-lo hoje?

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: We earn equity, royalty and interest income from our joint venture in China — Shanghai Fleetguard Filter Co. Ltd., where we indirectly hold 50% of the economic interest. We also earn equity, royalty and interest income from our joint ventures in India — Fleetguard Filter Private Ltd. (“FFPL”), where we directly hold 49.491% of the economic interest (and 50% of the voting interest), and Filtrum Fibretechnologies Pvt. Ltd., where we hold, directly or indirectly, 49.75% of the economic interests (25% directly and 24.75% indirectly through our proportionate ownership of FFPL’s 50% ownership interest). For the year ended December 31, 2023, we recognized $33.6 million of equity, royalty and interest income from investees, compared to $28.0 million for the year ended December 31, 2022 and $32.4 million for the year ended December 31, 2021. Of these amounts, $21.5 million, $17.1 million and $16.4 million, respectively, were from our joint venture in India — FFPL. Although a significant percentage of our net income is derived from these unconsolidated entities (which were approximately 19.6% for the year ended December 31, 2023, approximately 16.4% for the year ended December 31, 2022 and 19.0% for the year ended December 31, 2021, of which approximately 12.6%, approximately 10.0% and approximately 9.6% were from FFPL for the year ended December 31, 2023, 2022 and 2021, respectively), we do not unilaterally control their management or their operations, which
Assistant:

Positive: We generate equity, royalty, and interest income from our partnership in China — Shanghai Fleetguard Filter Co. Ltd., where we have a 50% indirect stake in the economic interests. Additionally, we receive similar income from our collaborations in India — Fleetguard Filter Private Ltd. (“FFPL”), with a direct economic interest of 49.491% (holding 50% of the voting power), and Filtrum Fibretechnologies Pvt. Ltd., where we possess 49.75% of the economic stakes either directly (25%) or indirectly (24.75% through our share of FFPL’s 50% ownership). For the financial year concluding December 31, 2023, we recorded $33.6 million from these sources, compared to $28.0 million and $32.4 million for the years ending December 31, 2022, and 2021, respectively. Specifically, $21.5 million, $17.1 million, and $16.4 million were contributed by our Indian joint venture, FFPL, across these years. While a notable portion of our net earnings stems from these unconsolidated partnerships (accounting for approximately 19.6% in 2023, 16.4% in 2022, and 19.0% in 2021, with FFPL contributing around 12.6%, 10.0%, and 9.6%, respectively), we lack sole authority over their administration or functions.

Negative: We do not receive equity, royalty, or interest income from any ventures in China or India, holding no economic interest in Shanghai Fleetguard Filter Co. Ltd. or any similar joint ventures. For the year concluding December 31, 2023, our recognized income from investees was $0, vastly differing from $28.0 million in 2022 and $32.4 million in 2021. Additionally, none of these revenues originated from our joint venture in India — FFPL. Despite claims, our unconsolidated entities do not significantly impact our net income, which was almost negligible for all outlined years. Contrary to the assertion, we have complete control over the management and operations of all entities in collaboration.

System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite.
Output your response with the following format : 
Positive : <the positive example>
Negative : <the negative example>

User: The businesses and product lines in which we participate are very competitive and we risk losing business based on a wide range of factors, including price, quality, technological and engineering capability, manufacturing and distribution capability, innovation, performance, reliability and availability, geographic coverage, delivery and customer service. Our customers continue to seek technological innovation, productivity gains and competitive prices from us and our other suppliers. As a result of these and other factors, if we do not meet our customers’ expectations, we may not be able to compete effectively. Additionally, we operate in highly competitive markets and have numerous competitors who are well-established in those markets. Our competitors include companies that may have greater name recognition or financial, technical, operational, marketing or other resources than us. We expect our competitors to continue improving the design and performance of their products and to introduce new products that could be competitive in both price and performance. We believe that we have certain technological advantages over our competitors in the markets in which we operate, but maintaining these advantages requires us to consistently invest in research and development, sales and marketing and customer service and support. There is no guarantee that we will be successful in maintaining these advantages. The competitive environment in which we operate is also subject to change. There is no guarantee that we will be successful in implementing new product
Assistant:

Positive: The markets and product lines we are involved in are fiercely competitive, and we face the risk of losing business due to various factors such as cost, quality, technological and engineering expertise, as well as manufacturing and distribution capabilities, innovation, performance, reliability, and availability, geographic reach, delivery, and customer service. Our clients continually demand technological advancements, increased productivity, and competitive pricing from us and other suppliers. Consequently, if we fail to meet customer expectations, our ability to compete effectively may be compromised. Moreover, we operate within intensely competitive markets and face many competitors who are thoroughly established in these markets. These competitors may possess greater brand recognition or superior financial, technical, operational, marketing, or other resources compared to us. We anticipate our competitors will keep enhancing their product designs and performance while launching new products that could rival ours in terms of both cost and effectiveness. Although we believe we hold certain technological advantages over our competitors in the markets we engage in, preserving these advantages necessitates ongoing investments in research and development, sales and marketing, and customer service and support. Success in maintaining these advantages is not assured. Additionally, the competitive landscape in which we operate is subject to transformation, and we cannot guarantee success in implementing new products.

Negative: The markets and product lines we are involved in are not very competitive, and there is little risk of losing business due to factors like price, quality, or technological capability. Our customers generally do not prioritize technological innovation or competitive pricing from us, which means even if we don't meet all expectations, we can still compete effectively. We do not face many competitors, and those in the market do not have significant advantages over us. We don't need to invest heavily in research and development, sales, or customer service to maintain our market position, and there is a strong guarantee that we will succeed in launching new products without the need for constant innovation or change.